8-K: Nuwellis CFO Resigns; CEO John Erb Appointed Interim CFO

Nuwellis, Inc. announced the resignation of its Chief Financial Officer, Robert B. Scott, and the appointment of President and CEO John L. Erb as interim CFO.

Summary

• Robert B. Scott notified Nuwellis, Inc. of his decision to resign as Chief Financial Officer on October 7, 2025.
• Mr. Scott's last day with the company is expected to be on or about October 24, 2025.
• His resignation is not the result of any disagreement with the company regarding its operations, policies, or procedures.
• The Board of Directors appointed John L. Erb, the company's President and Chief Executive Officer, as the interim Chief Financial Officer, interim Principal Financial Officer, and interim Principal Accounting Officer, effective on Mr. Scott's separation date.
• The company expects to commence a formal search process for a permanent Chief Financial Officer.
• Mr. Erb will not receive any additional compensation for assuming these interim roles.

Sentiment

Score: 6

Explanation: The departure of a CFO is generally a significant event, but the immediate appointment of a highly experienced CEO as interim, coupled with the explicit statement that the resignation was not due to disagreements, mitigates much of the potential negative impact. It suggests a planned and orderly transition rather than a crisis, leading to a neutral to slightly positive sentiment.

Positives

• The resignation of the CFO was not due to any disagreement with the company, suggesting an amicable and planned transition.
• John L. Erb, the current President and CEO, has been appointed interim CFO, providing immediate leadership continuity and leveraging his extensive experience with the company since 2012.
• Mr. Erb brings over two decades of executive and board experience in the medical device industry, including previous CEO roles at Nuwellis (formerly CHF Solutions, Inc.) and other medical device companies.

Negatives

• The departure of a key executive like the Chief Financial Officer can introduce a degree of uncertainty for investors and internal operations.
• The company will need to dedicate resources and time to conduct a formal search for a permanent CFO, which could be a lengthy process.
• The CEO taking on additional interim roles, while providing continuity, could potentially increase his workload and dilute focus, although his extensive experience mitigates this concern.

Risks

• Potential for operational disruption during the transition period as the company searches for a permanent Chief Financial Officer.
• Challenges in attracting and retaining a highly qualified permanent CFO in a competitive market.
• Increased workload and potential for stretched resources for the President and CEO while serving in multiple executive capacities.

Future Outlook

The company expects to commence a formal search process for the position of Chief Financial Officer to find a permanent replacement for the role.

Management Comments

• Mr. Scott's resignation is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or procedures.

Industry Context

Executive transitions, particularly in key financial roles, are common in the medical device industry. The appointment of an experienced CEO to an interim CFO position is a strategic move to ensure stability and continuity during the search for a permanent replacement, a practice often observed in companies prioritizing leadership consistency.

Management Changes

Stakeholder Impact

• Shareholders: May experience short-term uncertainty due to the executive change, but the appointment of an experienced interim CFO should provide stability. Long-term impact will depend on the selection of a permanent CFO.
• Employees: Potential for minor disruption within the finance department, but overall company stability is maintained by the CEO's interim role.
• Customers/Suppliers/Creditors: Unlikely to experience direct immediate impact as the change is internal and leadership continuity is maintained.

Next Steps

• Commence a formal search process for a permanent Chief Financial Officer.

Key Dates

Recommendation

While the departure of a CFO introduces some uncertainty, the immediate appointment of the highly experienced CEO, John L. Erb, as interim CFO provides stability and continuity. The explicit statement that the resignation was not due to disagreements is a positive signal, mitigating concerns about underlying operational issues. Investors should hold to observe the progress of the search for a permanent CFO and any subsequent strategic announcements, as the current situation suggests an orderly transition rather than immediate concern.

Keywords

Nuwellis, NUWE, CFO resignation, interim CFO, John L. Erb, Robert B. Scott, executive change, corporate governance, medical device